GCP
NVCT icon

GSA Capital Partners’s Nuvectis Pharma NVCT Stock Holding History

GSA Capital Partners’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,450
Closed -$141K – 1958
2025
Q3 		$141K Sell
23,450
-15,710
-40% -$108K 0.01% 1488
2025
Q2 		$293K Buy
39,160
+4,409
+13% +$40K 0.02% 1268
2025
Q1 		$340K Hold
34,751
– – 0.03% 1059
2024
Q4 		$188K Sell
34,751
-15,378
-31% -$96.3K 0.01% 1430
2024
Q3 		$315K Buy
50,129
+1,790
+4% +$11.8K 0.02% 1190
2024
Q2 		$306K Buy
48,339
+9,057
+23% +$61.6K 0.02% 1273
2024
Q1 		$322K Buy
39,282
+11,969
+44% +$102K 0.03% 1176
2023
Q4 		$228K Buy
+27,313
New +$244K 0.02% 1253

Other funds holding NVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

GSA Capital Partners's NVCT Position: Q4 2025 in Review

GSA Capital Partners sold out of Nuvectis Pharma (NVCT) in Q4 2025, closing a stake of 23,450 shares — an estimated $141K sold.

GSA Capital Partners first reported a position in NVCT in Q4 2023 and held it in 8 quarters. The position peaked at $340K in Q1 2025. 48 funds tracked by Wall St. Rank hold NVCT as of Q4 2025.

  • GSA Capital Partners reported no remaining Nuvectis Pharma position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 23,450 Nuvectis Pharma shares in Q4 2025, an estimated $141K.
  • GSA Capital Partners first reported a position in Nuvectis Pharma in Q4 2023 and held it in 8 quarters.
  • GSA Capital Partners's Nuvectis Pharma position peaked at $340K in Q1 2025.
  • 48 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.